Corvus Pharmaceuticals (CRVS) Short Interest Ratio & Short Volume $3.62 +0.10 (+2.84%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.64 +0.02 (+0.66%) As of 05/2/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Corvus Pharmaceuticals Short Interest DataCorvus Pharmaceuticals (CRVS) has a short interest of 5.34 million shares, representing 12.10% of the float (the number of shares available for trading by the public). This marks a 8.54% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.8, indicating that it would take 7.8 days of the average trading volume of 652,771 shares to cover all short positions.Current Short Interest5,340,000 sharesPrevious Short Interest4,920,000 sharesChange Vs. Previous Month+8.54%Dollar Volume Sold Short$17.30 millionShort Interest Ratio7.8 Days to CoverLast Record DateApril 15, 2025Outstanding Shares68,169,000 sharesShort Percent of Float12.10%Today's Trading Volume1,128,121 sharesAverage Trading Volume652,771 sharesToday's Volume Vs. Average173% Short Selling Corvus Pharmaceuticals? Sign up to receive the latest short interest report for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCRVS Short Interest Over TimeCRVS Days to Cover Over TimeCRVS Percentage of Float Shorted Over Time Corvus Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20255,340,000 shares $17.30 million +8.5%12.1%7.8 $3.24 3/31/20254,920,000 shares $15.65 million -8.7%11.1%7.9 $3.18 3/15/20255,390,000 shares $24.36 million +0.8%12.2%6.2 $4.52 2/28/20255,350,000 shares $21.61 million -6.6%12.1%5.8 $4.04 2/15/20255,730,000 shares $27.96 million -6.2%13.0%6.2 $4.88 1/31/20256,110,000 shares $32.75 million +11.1%N/A6.2 $5.36 1/15/20255,500,000 shares $27.06 million +1.3%N/A4.9 $4.92 12/31/20245,430,000 shares $29.05 million +26.0%N/A4.7 $5.35 12/15/20244,310,000 shares $31.81 million +22.8%N/A4 $7.38 11/30/20243,510,000 shares $31.91 million +6.4%N/A4.5 $9.09 Get the Latest News and Ratings for CRVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 11/15/20243,300,000 shares $27.03 million +12.6%N/A4.5 $8.19 10/31/20242,930,000 shares $25.90 million +20.1%N/A4.6 $8.84 10/15/20242,440,000 shares $16.40 million +13.5%N/A4.6 $6.72 9/30/20242,150,000 shares $11.35 million +31.1%N/A5.4 $5.28 9/15/20241,640,000 shares $8.36 million +14.7%N/A4.5 $5.10 8/31/20241,430,000 shares $6.41 million +4.4%N/A4.9 $4.48 8/15/20241,370,000 shares $5.21 million +19.1%N/A5.3 $3.80 7/31/20241,150,000 shares $2.96 million -8.0%N/A4.7 $2.57 7/15/20241,250,000 shares $2.50 million -12.6%N/A5.8 $2.00 6/30/20241,430,000 shares $2.60 million -4.7%N/A6.6 $1.82 6/15/20241,500,000 shares $3.06 million -1.3%N/A6.5 $2.04 5/31/20241,520,000 shares $3.28 million +17.8%N/A6.5 $2.16 5/15/20241,290,000 shares $2.86 million -5.2%N/A5.2 $2.22 4/30/20241,360,000 shares $2.11 million -0.7%3.7%5.4 $1.55 4/15/20241,370,000 shares $2.01 million -2.1%3.7%7 $1.47 3/31/20241,400,000 shares $2.49 million -6.0%3.8%6.6 $1.78 3/15/20241,490,000 shares $2.83 million +17.3%4.0%6.8 $1.90 2/29/20241,270,000 shares $2.84 million No Change3.4%5.7 $2.24 2/15/20241,270,000 shares $2.98 million -8.0%3.4%6.2 $2.35 1/31/20241,380,000 shares $2.76 million -1.4%3.7%6.3 $2.00 1/15/20241,400,000 shares $3.28 million +5.3%3.8%6 $2.34 12/31/20231,330,000 shares $2.34 million +2.3%3.6%6.1 $1.76 12/15/20231,300,000 shares $1.99 million -17.2%3.5%6.5 $1.53 11/30/20231,570,000 shares $2.40 million -12.3%4.3%7.9 $1.53 11/15/20231,790,000 shares $2.70 million +4.7%4.9%6.4 $1.51 10/31/20231,710,000 shares $1.93 million -3.4%4.6%6.4 $1.13 10/15/20231,770,000 shares $2.48 million No Change4.8%7.1 $1.40 9/30/20231,770,000 shares $2.58 million -2.8%4.8%6.1 $1.46 9/15/20231,820,000 shares $2.88 million +32.9%4.9%5 $1.58 8/31/20231,370,000 shares $2.90 million +21.2%3.8%2.3 $2.12Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/15/20231,130,000 shares $2.44 million -2.6%3.1%1.8 $2.16 7/31/20231,160,000 shares $2.61 million -17.7%3.4%1.1 $2.25 7/15/20231,410,000 shares $3.47 million +11.9%4.1%1.3 $2.46 6/30/20231,260,000 shares $2.89 million +61.4%3.7%1.1 $2.29 6/15/2023780,600 shares $1.94 million -19.8%2.3%0.7 $2.49 5/31/2023973,100 shares $2.96 million +113.6%2.8%1.1 $3.04 5/15/2023455,500 shares $1.18 million +209.2%1.3%0.6 $2.60 4/30/2023147,300 shares $159,084.00 -38.3%0.4%0.6 $1.08 4/15/2023238,700 shares $248,248.00 +50.8%0.7%1.1 $1.04 3/31/2023158,300 shares $144,053.00 -20.9%0.5%0.8 $0.91 3/15/2023200,200 shares $144,144.00 +16.9%0.6%2.1 $0.72 2/28/2023171,200 shares $124,976.00 +35.9%0.5%1.4 $0.73 2/15/2023126,000 shares $97,007.40 +13.7%0.4%1 $0.77 1/31/2023110,800 shares $90,856.00 -34.9%0.3%0.8 $0.82 1/15/2023170,100 shares $154,791.00 -3.7%0.5%1.2 $0.91 12/30/2022176,700 shares $150,195.00 +17.3%0.5%1.2 $0.85 12/15/2022150,600 shares $126,353.40 -53.8%0.4%1 $0.84 11/30/2022325,900 shares $303,803.98 +58.1%0.9%2.2 $0.93 11/15/2022206,100 shares $187,963.20 -0.5%0.6%1.3 $0.91 10/31/2022207,100 shares $179,555.70 -12.4%0.6%1 $0.87 10/15/2022236,500 shares $215,215.00 +16.3%0.7%0.9 $0.91 9/30/2022203,300 shares $166,401.05 +1.6%0.6%0.7 $0.82 9/15/2022200,200 shares $191,191.00 +70.8%0.6%0.6 $0.96 8/31/2022117,200 shares $112,336.20 -64.5%0.3%0.4 $0.96 8/15/2022330,500 shares $371,812.50 -75.2%1.0%1.1 $1.13 7/31/20221,330,000 shares $1.17 million +70.1%3.9%4.7 $0.88 7/15/2022782,000 shares $774,962.00 -15.2%2.3%3.2 $0.99 6/30/2022922,500 shares $913,367.25 +306.2%2.7%3.6 $0.99 6/15/2022227,100 shares $224,806.29 +18.5%0.7%0.9 $0.99 5/31/2022191,600 shares $197,348.00 -22.9%0.6%0.8 $1.03 5/15/2022248,600 shares $258,544.00 +28.6%0.7%1 $1.04 4/30/2022193,300 shares $253,223.00 +5.2%0.6%0.8 $1.31 4/15/2022183,800 shares $266,510.00 -14.9%0.5%0.7 $1.45 3/31/2022215,900 shares $354,076.00 +5.2%0.6%0.7 $1.64 3/15/2022205,200 shares $299,592.00 +3.0%0.6%0.6 $1.46 2/28/2022199,200 shares $352,584.00 -41.3%0.6%0.5 $1.77 2/15/2022339,300 shares $692,172.00 +101.5%1.0%0.7 $2.04 1/31/2022168,400 shares $303,120.00 -43.8%0.5%0.3 $1.80 1/15/2022299,500 shares $673,875.00 +34.0%N/A0 $2.25 12/31/2021223,500 shares $538,635.00 -31.2%0.7%0.3 $2.41 12/15/2021324,700 shares $892,925.00 -43.0%1.0%0.2 $2.75 11/30/2021569,200 shares $1.94 million -45.8%1.9%0.1 $3.41 11/15/20211,050,000 shares $3.89 million -42.9%3.5%0.1 $3.70 10/29/20211,840,000 shares $8.34 million +3.4%6.2%0.2 $4.53 10/15/20211,780,000 shares $8.81 million -42.2%6.3%0.2 $4.95 9/30/20213,080,000 shares $14.91 million +318.7%10.9%0.4 $4.84 9/15/2021735,600 shares $1.68 million +45.0%2.5%0.1 $2.29 8/31/2021507,200 shares $1.15 million -48.0%1.8%2.1 $2.26 8/13/2021975,800 shares $1.93 million -22.6%3.5%4.4 $1.98 7/30/20211,260,000 shares $2.63 million +3.3%4.5%5.3 $2.09Elon’s Terrifying Warning Forces Trump To Take Action (Ad)Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...Get your free gold guide! 7/15/20211,220,000 shares $2.84 million +0.8%3.7%4.1 $2.33 6/30/20211,210,000 shares $3.23 million +7.1%3.7%4.2 $2.67 6/15/20211,130,000 shares $3.10 million -8.9%3.4%3.5 $2.74 5/28/20211,240,000 shares $3.40 million +3.3%3.8%3.4 $2.74 5/14/20211,200,000 shares $2.95 million -9.1%N/A2.1 $2.46 4/30/20211,320,000 shares $3.72 million -1.5%N/A1.4 $2.82 4/15/20211,340,000 shares $3.79 million -7.6%N/A1.5 $2.83 3/31/20211,450,000 shares $4.26 million -8.2%N/A1.6 $2.94 3/15/20211,580,000 shares $5.10 million +24.4%N/A1.8 $3.23 2/26/20211,270,000 shares $4.55 million +2.4%N/A1.5 $3.58 2/12/20211,240,000 shares $4.89 million +0.8%N/A1.8 $3.94 1/29/20211,230,000 shares $4.54 million No Change5.7%5 $3.69 1/15/20211,230,000 shares $5.08 million +2.5%5.7%6.6 $4.13 12/31/20201,200,000 shares $4.52 million -3.2%5.6%6.8 $3.77 12/15/20201,240,000 shares $4.90 million -10.1%5.8%1.5 $3.95 11/30/20201,380,000 shares $5.56 million -0.7%6.4%1.6 $4.03 11/15/20201,390,000 shares $5.74 million -9.2%6.5%1.6 $4.13 10/30/20201,530,000 shares $6.10 million +2.7%7.1%1.7 $3.99 10/15/20201,490,000 shares $5.96 million +8.8%6.9%1.6 $4.00 9/30/20201,370,000 shares $5.49 million -14.4%6.4%1.3 $4.01 9/15/20201,600,000 shares $6.75 million -1.2%7.5%0.8 $4.22 8/31/20201,620,000 shares $6.14 million +2.5%7.6%0.8 $3.79 8/14/20201,580,000 shares $6.35 million -2.5%7.4%0.8 $4.02 7/31/20201,620,000 shares $6.87 million +25.6%7.6%0.8 $4.24 7/15/20201,290,000 shares $4.91 million +204.1%6.0%0.6 $3.81 6/30/2020424,200 shares $1.15 million +0.3%2.1%0.2 $2.72 6/15/2020422,900 shares $1.31 million +29.0%2.1%3.2 $3.10 5/29/2020327,800 shares $1.20 million -72.5%1.7%2.2 $3.66 5/15/20201,190,000 shares $4.18 million -4.0%6.0%7.9 $3.51 CRVS Short Interest - Frequently Asked Questions What is Corvus Pharmaceuticals' current short interest? Short interest is the volume of Corvus Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of April 15th, investors have sold 5,340,000 shares of CRVS short. 12.10% of Corvus Pharmaceuticals' shares are currently sold short. Learn More on Corvus Pharmaceuticals' current short interest. What is a good short interest ratio for Corvus Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CRVS shares currently have a short interest ratio of 8.0. Learn More on Corvus Pharmaceuticals's short interest ratio. Which institutional investors are shorting Corvus Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Corvus Pharmaceuticals: Wolverine Trading LLC, LMR Partners LLP, Group One Trading LLC, Citadel Advisors LLC, Jane Street Group LLC, Boothbay Fund Management LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., and ADAR1 Capital Management LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Corvus Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 12.10% of Corvus Pharmaceuticals' floating shares are currently sold short. Is Corvus Pharmaceuticals' short interest increasing or decreasing? Corvus Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,340,000 shares, an increase of 8.5% from the previous total of 4,920,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Corvus Pharmaceuticals' short interest compare to its competitors? 12.10% of Corvus Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Corvus Pharmaceuticals: X4 Pharmaceuticals, Inc. (5.24%), Enliven Therapeutics, Inc. (23.47%), Collegium Pharmaceutical, Inc. (14.46%), Pharvaris (3.20%), Spyre Therapeutics, Inc. (22.97%), Mineralys Therapeutics, Inc. (15.91%), Intellia Therapeutics, Inc. (28.92%), Nurix Therapeutics, Inc. (20.43%), Gyre Therapeutics, Inc. (14.16%), Arcus Biosciences, Inc. (14.86%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Corvus Pharmaceuticals stock? Short selling CRVS is an investing strategy that aims to generate trading profit from Corvus Pharmaceuticals as its price is falling. CRVS shares are trading up $0.10 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Corvus Pharmaceuticals? A short squeeze for Corvus Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CRVS, which in turn drives the price of the stock up even further. How often is Corvus Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CRVS, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies XFOR Short Interest Data ELVN Short Interest Data COLL Short Interest Data PHVS Short Interest Data SYRE Short Interest Data MLYS Short Interest Data NTLA Short Interest Data NRIX Short Interest Data GYRE Short Interest Data RCUS Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CRVS) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CRVS Stock Free CRVS Stock Alerts